<DOC>
	<DOC>NCT02955394</DOC>
	<brief_summary>This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery after ~4 months on treatment.</brief_summary>
	<brief_title>Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer</brief_title>
	<detailed_description>This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery after ~4 months on treatment. After consent, all patients will get a tissue biopsy, and than half the patients will get fulvestrant alone (standard dosing) and the other half of the patients will get fulvestrant plus enzalutamide. At ~4 weeks, a biopsy will be done and therapy will be continued. Hormone therapy will continue for ~4 months at which point the patients will undergo surgical resection.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>ER+ Her2 breast cancer Stage at least T2 or greater Planned to get local surgery Postmenopausal, or if pre or peri menopausal, then will need to have concurrent ovarian suppression. At least 18 years of age Not on anticoagulants PS 02 Able to swallow study drug and comply with study requirements ANC &gt;1000/uL, platelets &gt;75,000/uL at screening visit Total bilirubin &lt; 1.5 times upper limit of normal (ULN) at the screening visit unless an alternate nonmalignant etiology exists (eg, Gilbert's disease) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 3 times ULN or &lt; 5 times ULN if patient has documented liver metastases Creatinine &lt; 1.5 times ULN INR &lt; 1.5 times ULN, or if on warfarin, can safely transition off for biopsy Willing to donate blood for research at 4 time points Willing to undergo core biopsies for research at study entry and at ~4 weeks. Willing to donate tissue to research from the surgical specimen Written informed consent obtained prior to biopsies and blood samples Current or previously treated brain or leptomeningeal metastases History of seizures Prior treatment with an antiandrogen (abiraterone, ARN509, bicalutamide, enzalutamide, ODM201, TAK448, TAK683, TAK700, VT464). Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal estrogens are allowed if necessary for patient comfort.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ER+/Her2 - breast cancer</keyword>
	<keyword>Preoperative Fulvestrant</keyword>
	<keyword>Enzalutamide</keyword>
</DOC>